Key findings of the APRES study

Prof. François Schellevis MD PhD John Paget MSc PhD on behalf of the APRES study group





Motivation for APRES

Primary care physicians need to know which antibiotic to prescribe, taking effectiveness and resistance into account

- Overall levels of antimicrobial resistance are increasing in Europe
- Over 90% of antibiotics for human use are prescribed in primary care
- Information about antimicrobial resistance in the community is lacking





Provide information and recommendations on the appropriateness of prescribing antibiotics in primary care in Europe



APRES project features

- <u>Appropriateness of PRES</u>cribing antibiotics in primary care to control resistance in Europe
- EU funded study 2.8 million€
- 4 ¹/₂ year project: October 2009-March 2014
- 14 Partners in 9 countries
- 8 national laboratories / 1 central laboratory
- Core partners: NIVEL, Universities of Nottingham, Antwerp, Maastricht





Collaborative approach





Participating countries





WP 1: Literature review (Uni Nottingham)

- Aim: to assess the relationship between the antibiotic resistance pattern of bacteria circulating in the community and the consumption of antibiotics in the community
- 243/974 studies eligible for inclusion
- Positive relationship was found between antibiotic consumption and resistance
- Meta-analysis generated a pooled odds ratio (effect size) of 2.3 (95% Cl 2.2 to 2.5)
- Countries in southern Europe showed a stronger link between consumption and resistance than other regions

WP 2: Antibiotic resistance (Uni Maastricht)

- Aim: to assess the resistance pattern of S. Aureus and S. Pneumoniae isolated from 36,000 healthy visitors of GP practices in 9 countries
- Main inclusion criteria:
 - Age: 4 years and older
 - Presenting with a non-infectious disorder
- Nasal swabs from N=32,206 GP practice visitors
- National microbiological labs: isolation of *S. aureus* and *S. Pneumoniae*
- Laboratory Uni Maastricht: antibiotic resistance testing

WP 2: Antibiotic resistance (Uni Maastricht)



WP 2: Antibiotic resistance (Uni Maastricht)

Main findings: S. Aureus resistance

- High level of penicillin resistance: 65-87%
- Sweden is the champion: for 6 (/ 8) antibiotics lowest resistance rates
- Highest resistance rates:
 - Azithromycin France (17%)
 - Erythromycin France (17%)
 - Clindamycin Belgium (15%)
 - Tetracycline Croatia (7%)
 - Ciprofloxacin UK (5%)

WP 3: Antibiotic prescribing patterns (Uni Antwerp)

- Aim: to assess the antibiotic prescribing patterns of primary care physicians in 9 European countries
- Electronic prescription data from 187 practices (2010)
- Practice denominator data (total population covered: N=1,2 million people)
- Calculation of Daily Defined Doses (DDDs)

WP 3: Antibiotic prescribing patterns (Uni Antwerpen)



WP 3: Antibiotic prescribing patterns (Uni Antwerp)

Main findings

- Highest vs lowest prescription rates: 750 vs 200 DDDs per 100 active patients in 2010
- High within-country variation: Hungary, Spain, Belgium
- Lower prescription rates in France than expected

WP 4: Appropriateness of treatment guidelines and antibiotic prescriptions (NIVEL)

Aim: to assess the appropriateness of primary care treatment guidelines taking into account the antibiotic resistance patterns in 9 European countries

Method: Compare 13 national treatment guidelines for *S. aureus* related skin infections

Conclusions:

- a) Consensus: mainly β-lactam antibiotics
- b) Recommended dosages vary from 5-9 DDDs
- c) Few guidelines based on national resistance data
- d) Treatment guidelines in accordance with resistance patterns

Theoretical effectiveness of relevant antibiotic treatment of S. aureus infections (incl Penicillin)







Theoretical effectiveness of relevant antibiotic treatment of S. aureus infections (excl Penicillin)



Effectiveness



Results of APRES

- Analyses to be finalized:
 - Resistance patterns S. Pneumoniae
 - Appropriateness of prescribed antibiotics
- So far, 5 articles in peer reviewed scientific journals, including The Lancet Infectious Diseases
- One PhD graduate and two PhD candidates
- Link with other key scientific projects (e.g. GRACE)
- Link with key public health organisations (national authorities, ECDC, WHO)





Conclusions

- Basis for evidence based recommendations for appropriately prescribing antibiotics in primary care in Europe
- Resistance levels for S. Aureus in the community are variable across Europe, but generally low (incl. MRSA)
- Antibiotic prescription patterns vary, with the lowest levels in western and northern Europe
- Treatment guidelines for S. Aureus skin infections are generally appropriate
- Theoretical effectiveness of antibiotic treatment of S. aureus infections: 90-99%





APRES consortium is a good network for European studies in primary care



Thank you for your attention